Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson Cancer Center
Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson Cancer Center
复制标题
DOI：
10.1016/j.eururo.2012.04.020
复制
发表时间：
2013-08-01
期刊：
影响因子：
23.4
通讯作者：
Siefker-Radtke, Arlene
中科院分区：
文献类型：
--
作者：
Lynch, Siobhan P.;Shen, Yu;Siefker-Radtke, Arlene
背景：小细胞尿路上皮癌（SCUC）是一种罕见的侵袭性恶性肿瘤，易发生早期显微转移。数据显示，与初始手术相比，新辅助化疗可提高生存率。目的：在一项大型单机构队列研究中，探讨新辅助化疗对急性骨鳞癌患者生存的影响。设计、环境和参与者：1985年至2010年间，172名患者在MD安德森癌症中心（MDACC）接受了SCUC治疗。收集并分析临床、病理和手术资料。结果测量和统计分析：采用Kaplan-Meier法计算总生存期（OS）和疾病特异性生存期（DSS）。采用多变量Cox比例风险模型评价新辅助化疗对生存率的影响。结果与局限性：125例可切除病变患者(
Background: Small cell urothelial carcinoma (SCUC) is a rare, aggressive malignancy with a propensity for early microscopic metastases. Data suggest that neoadjuvant chemotherapy may lead to improved survival compared with initial surgery.Objective: To determine the influence of neoadjuvant chemotherapy on survival of SCUC patients in a large single-institution cohort.Design, setting, and participants: Between 1985 and 2010, 172 patients were treated for SCUC at MD Anderson Cancer Center (MDACC). Clinical, pathologic, and surgical data were collected and analyzed.Outcome measurements and statistical analysis: Overall survival (OS) and disease-specific survival (DSS) were calculated using the Kaplan-Meier method. Multivariable Cox proportional hazards models were used to evaluate the effects of neoadjuvant chemotherapy on survival.Results and limitations: Of 125 patients with resectable disease (